SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst intense community debate surrounding Donald Trump's State of the Union address, with supporters lauding his performance and policies while critics denounce his rhetoric and character, driving highly polarized sentiment for the Trump-affiliated company.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The State of the Union address and its highly polarized reception are driving discussions around SPY, with community members fiercely debating economic claims, tariffs, and political division, while anticipating upcoming NVIDIA earnings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following news of its shift to U.S. Mac Mini and AI server production in Houston, alongside a Supreme Court ruling that removed a significant tariff burden. The community is actively discussing whether these strategic moves and evolving AI ambitions cement Apple's position as a market leader or if underlying economic uncertainties temper the immediate bullish sentiment.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending amidst high trading volume and strong community speculation around a significant short squeeze, driven by enthusiasm for its Anktiva cancer treatment and recent public presentations highlighting its chemo-free approach, overshadowing varied investor reactions to the State of the Union address.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending due to intense bidding, as its board re-evaluates a sweetened all-cash acquisition offer from Paramount Skydance, which includes a ticking fee and covers Netflix's breakup fee. Community discussion centers on the certainty of Paramount's proposal versus Netflix's existing bid, with shareholders debating potential regulatory hurdles and whether Netflix will counter.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending ahead of its earnings report, fueling a sharp debate as the broader software sector grapples with AI disruption fears and recent analyst downgrades. Bulls argue the stock is deeply undervalued with strong AI integration, while bears anticipate further pressure.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

PSKY is trending as Warner Bros. Discovery's board re-evaluates its increased acquisition bid against Netflix's, sparking community debate over the debt implications for PSKY versus the perceived strategic advantages of a combined entity and the regulatory hurdles facing Netflix's offer.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending following an earnings beat driven by strong revenue growth and significant new restaurant openings, sparking a debate among investors. The community is sharply divided between those who see its premium valuation as justified by a clear long-term growth trajectory and popular healthy menu, and those who highlight moderating same-store sales and potential margin pressures compared to peers.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar (XLM) is trending as community discussion centers on its growing utility and institutional adoption, fueled by CME Group's plans for XLM futures and the live launch of its X-Ray privacy protocol on Mainnet, enhancing privacy on the network.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as the market anticipates an imminent, transformative $1.5 billion contract with Applied Digital to provide rapid, natural gas-powered energy solutions for an AI data center. This outlook is further boosted by recent White House focus on off-grid power for the sector, with the community highlighting BW's ability to quickly deploy crucial infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.</li><li>Separately, AstraZeneca announced that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of lung cancer.</li></ul>Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.Modella <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale">said</a> that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. This would allow for the generation of new insights and allow for greater automation across workflows, the company said.Shares of AZN traded marginally in the green at the time of writing.<h2 class="st-heading-2">Partnership To Acquisition</h2>Modella announced a multi-year deal with AstraZeneca in 2025 aimed at integrating its generative and agentic AI platform into AstraZeneca’s oncology research and development organization.The collaboration was aimed at supporting efforts to accelerate clinical development and enhancing biomarker discovery.<h2 class="st-heading-2">First Patient Dosing In New Late-Stage Trial</h2>Separately, AstraZeneca announced earlier on Tuesday that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of locally advanced or metastatic nonsquamous non-small cell lung cancer. Lung cancer is the most common cancer globally.Datroway, meanwhile, is a cancer drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AZN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that AstraZeneca must try to acquire smaller drugmaker Omeros Corp.<stembedurl>https://www.stocktwits.com/resq1/message/641646825</stembedurl><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 

Equity

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 


<ul class="summary-bullets"><li>MSCI, earlier had proposed to exclude crypto treasury firms from its global indexes.</li><li>MSCI said current index treatment of DATCOs identified in the preliminary list will remain unchanged.</li><li>Shares of DAT firms rallied after the announcement.&nbsp; &nbsp;</li></ul>MSCI said on Tuesday that it has decided not to implement the proposal to exclude digital asset treasury companies (DATCOs) from the MSCI Global Investable Market Indexes (MSCI Indexes) as part of the February 2026 Index Review.&nbsp;DATCOs currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said.&nbsp;However, MSCI intends to open a broader consultation on the treatment of non-operating companies in general. MSCI had earlier proposed to exclude crypto treasury firms from its global indexes. &nbsp;The consultation results were scheduled to be announced by January 15, 2026.&nbsp;Shares of one of the biggest DAT companies, Michael Saylor-backed Strategy, rallied more than 5% after the announcement. Meanwhile, Bitmine Immersion shares jumped 2.3% and Strive Asset Management shares were up 1.9% during after market hours of trading.&nbsp;MSCI said that the current index treatment of DATCOs identified in the preliminary list published by MSCI of companies whose digital asset holdings represent 50% or more of their total assets will remain unchanged.&nbsp;MSCI did flag that feedback from the consultation confirmed institutional investor concern that some DATCOs exhibit characteristics similar to investment funds, which are not eligible for inclusion in the MSCI Indexes.&nbsp;<h2 class="st-heading-2">DATs Rise</h2>Firms globally are adopting DATs to put digital currencies on their balance sheets, as interest in the sector continues to surge.&nbsp;Easing regulations around cryptocurrencies and broader acceptance of tokens for transactions has also helped several companies turn their operations into DATs or launch their subsidiaries as DATs.&nbsp;One of the biggest DAT companies is Michael Saylor-backed Strategy (MSTR), which began buying bitcoin in 2020 and has been continuing to do so ever since. Notably, the number of DAT companies has expanded over the years.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around MSTR trended in ‘extremely bullish’ territory amid ‘high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

This photo shows a smartphone screen displaying the Bitcoin cryptocurrency logo.

MSTR, BMNR, ASST Shares Rally After MSCI Decides To Not Exclude Digital Asset Treasury Firms From Its Indexes

Digital asset treasury companies currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said. 

Mag 7 Beats S&P 500 in Q3: Buy These 3 ETFs to Tap Their Strength

ETFs like XLG provide a diversified way to benefit from the Mag 7's Q3 earnings surge and the positive momentum expected going forward.

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) on Friday launched an at-home delivery service for its Flumist influenza vaccine ahead of the upcoming flu season.Flumist is a vaccine that is sprayed into the nose to help protect against influenza in people aged two through 49 years. However, it may not prevent influenza in everyone who gets vaccinated, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250815310613/en/FLUMIST-Influenza-Vaccine-Live-Intranasal-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery">stated</a>.The vaccine was initially approved by the U.S. Food and Drug Administration in 2003. It can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals aged 2-17 years.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Adults aged 18 and older can visit the Flumist website and click to order, following which they will be directed to complete a medical screening questionnaire. These submissions will then be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, to determine eligibility.Once eligibility is confirmed and insurance verified, the vaccine will be prescribed and shipped to the consumer’s home by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages.The vaccine will be delivered with clear administration instructions, storage guidance, and disposal instructions, AstraZeneca said. Once received, the vaccine should be stored in the refrigerator until use. The home delivery service will be available only in 34 states for the upcoming flu season due to local pharmacy laws, the company said. However, AstraZeneca is eyeing making the service available across all 48 contiguous states in future seasons.Flumist, meanwhile, will continue to be available in doctors’ offices and pharmacies for administration by healthcare professionals across the nation, the company added.AZN stock is up by 20% this year but down by about 8% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/big-short-investor-michael-burry-cuts-stake-in-estee-lauder/chsPoDFRdfW">‘Big Short’ Investor Michael Burry Cuts Stake In Estee Lauder By A Whopping 25% – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with placebo at 12 weeks in a late-stage study evaluating the drug in uncontrolled or treatment-resistant hypertension.Nasdaq-listed shares of the company traded 0.3% higher at the time of writing.The reduction in systolic blood pressure was both statistically significant and clinically meaningful, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html">said</a> in a statement. Baxdrostat was generally well tolerated with a favourable safety profile in the trial, where patients with uncontrolled or treatment-resistant hypertension received the investigational drug or placebo on top of standard of care.According to <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a>, there are 1.3 billion people worldwide living with hypertension, a medical condition characterised by consistently high blood pressure levels, which can, over time, damage blood vessels and vital organs. While uncontrolled hypertension persists despite treatment with two or more medications, resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.A key contributor to hypertension is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Baxdrostat is an oral, small-molecule investigational drug that inhibits an enzyme responsible for the synthesis of aldosterone in the adrenal gland.AstraZeneca acquired Baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash is payable to former CinCor shareholders upon the submission of a new drug application either in the U.S. or Europe.AstraZeneca said on Monday that the data from the late-stage trial will be shared with regulatory authorities around the world, but did not detail when it will seek approval for the drug from the U.S. Food and Drug Administration.Baxdrostat is currently being investigated in clinical trials for hypertension, primary aldosteronism, chronic kidney disease, and the prevention of heart failure in high-risk hypertensive patients.On Stocktwits, retail sentiment around AstraZeneca is unchanged within the ‘neutral’ territory over the past 24 hours, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_9_51_14_AM_png_716900ba11.webp" alt="AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>AZN stock was up by 9% this year but down by about 9% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gsk-seeks-fda-approval-for-rsv-vaccine-in-more-adults/ch8ByXHR5Vp">GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React

The reduction in systolic blood pressure in the trial was both statistically significant and clinically meaningful, the company said in a statement.

Invesco Exchange-Traded Fund Trust II - Invesco ESG NASDAQ 100 ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$41.54
Prev Close	$41.02
Open	$41.13
Dividend Yield	N/A
50-Day Moving Average	$42.39
Beta	N/A
Avg. Volume	35,517.35
PE Ratio	N/A

52-Week High	$44.04
52-Week Low	$27.34
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

QQMG
Invesco ESG NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQMG News

QQMGInvesco ESG NASDAQ 100 ETF